Dose estimation for renal-excretion drugs in neonates and infants based on physiological development of renal function

Yakugaku Zasshi

Volumn 129, Issue 7, 2009, Pages 829-842

  Suzuki, Shinya ^a,b   Murayama, Yuka ^a   Sugiyama, Erika ^a   Sekiyama, Masao ^b   Sato, Hitoshi ^a  

^a SHOWA UNIVERSITY   (Japan)

^b Kanagawa Prefectural Keiyukai Keiyu Hospital   (Japan)

Author keywords

Dose estimation; Glomerular filtration rate; Infant; Neonate; Tubular secretion clearance; Unbound fraction of drug in plasma

Indexed keywords

AMOXICILLIN; DIGOXIN; FOSFOMYCIN; HABEKACIN; NORFLOXACIN; VANCOMYCIN;

ADULT; ARTICLE; BODY SURFACE; CHILD; CONTROLLED STUDY; DOSE CALCULATION; DRUG CLEARANCE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFANT; KIDNEY FUNCTION; MALE; NEWBORN; PRESCHOOL CHILD; URINARY EXCRETION;

ANTI-BACTERIAL AGENTS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY; MALE; METABOLIC CLEARANCE RATE;

EID: 67650076832     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.129.829     Document Type: Article

References (34)

1. Morita S., Oonishi K., Report for Health Science Reseach in 1998-2000., 49-100 (2001).
2. Johnson T. N., Rostami-Hodjegan A., Tucker G. T., Clin. Phamacokinet., 45, 931-956 (2006).
3. Investigation Report on Physical Development of Infants and Early Children in 2000 (Ministry of Health and Labor, Japan).
4. Investigation Report on School Health statistics in 2000 (Ministry of Education and Science, Japan).
5. Murakawa K., Murakawa T., Sakamoto H., Fukada S., Konishi T., Nishida M., Antimicrob. Agents Chemother., 21, 224-230 (1982).
6. Interview Form of FOSMICIN®(Meiji Seika Kaisha Co).
7. Interview Form of Baccidal® Tablets for Children (Kyorin Pharmaceutical Co).
8. Hardman J. G., Limbird L. E., Gilman A. G., "Goodman and Gilman's the pharmacological basis of therapeutics," 10th ed., New York, Macmillan Pub Co., New York., 2001.
9. Sato K., Fukui M., Araki Y., Takahashi M., Tamura S., Takahira H., Jpn. J. Chemother., 21, 1383-1391 (1973).
10. Interview Form of Sawacillinn®(Astellas Pharmaceutical Co).
11. Bennett W. M., "Clinical Phamacokinet Drug Data Handbook," 3rd ed., ADIS International company., Auckland, 1998.
12. Zokufa H. Z., Solem L. D., Rodvold K. A., Crossley K. B., Fischer J. H., Rutschafer J. C., Journal of Burn Care and Rehabilitation, 10, 425-428 (1989).
13. Michael E. Winter., "Basic Clinical Pharmacokinetics Fourth Edition," Technomics Inc, Tokyo, 2005.
14. Yasuhara M., Iga T., Zenda H., Okumura K., Oguma T., Yano Y., Hori R., Ther. Drug. Monitor., 20, 612-618 (1998).
15. Yasuhara M., Iga T., Zenda H., Okumura K., Oguma T., Yano Y., Hori R., Ther. Drug. Monitor., 20, 139-148 (1998).
16. Totsuka K., Shimizu K., Mitomi N., Niizato T., Araake M., Jpn. J. Antibiotics, 47, 676-692 (1994).
17. Mitomi N., Matsumoto T., Fujigaki M., Komiya I., Kai F., Jpn. J. Antibiotics, 357-363 (1987).
18. Interview Form of HABEKACIN®(Meiji Seika Kaisha Co).
19. Sato N., Shibutani S., Sibasaki S., Jpn. J. Ther. Drug Monitor., 24, 86-97 (2007).
20. Tanigawara Y., Sato R., Morita K., Kaku M., Aikawa N., Shimizu K., Antimicrob. Agents Chemother., 50, 3754-3762 (2006).
21. Ritchael W. A., "Graphic Approach to Clinical Pharmacokinetics, " Yakuji Nippo Ltd, Tokyo, 1998, pp. 155-162.
22. Interview Form of DIGOSIN®(Chugai Pharmaceutical Co).
23. Suematsu F., Yukawa E., Yukawa M., Minemoto M., Ohdo S., Higuchi S., Goto Y., Eur. J. Clin. Pharmacol., 57, 19-24 (2001).
24. Hori R., Miyazaki K., Mizugaki M., Ogata H., Goto M., Ichimura F., Yasuhara M., Tanigawara Y., Hashimoto Y., Koue T., Mimaki T., Tanaka K., Okumura K., Gomita H., Higuchi S., Jpn. J. Ther. Drug Monitor., 11, 7-17 (1994).
25. Tsuji S., Morita S., Gekkan Yakuji, 45, 1807- 1813 (2003).
26. Yoshioka Y., Tsukada Y., Tetsuou Y., Nagasawa K., Murata M., "Handbook for reading medical record cards," JIHO., Tokyo, 2007.
27. Takao A., Monma K., Nakazawa M., Nakanishi T., "Clinical Developmental Cardiology," 3rd ed., Chugai-Igakusha, Tokyo, pp. 916 (2005).
28. Interview Form of WIDECILLIN®(Meiji Seika Kaisha Co).
29. Sheiner L. B., Beal S. L., J. Pharmacokinet. Biopharm., 9, 503-512 (1981).
30. Echizen H., Pediatrics of Japan, 47, 583-588 (2006).
31. Kato H., The Journal of Practical Pharmacy, 55, 2305-2313 (2004).
32. Fujii R., Fujita K., Sakata Y., Abe T., Tajima T., Terashima I., Meguro H., Watanabe N., Mikuni K., Sakai T., Kasai N., Sunagawa K., Iwata S., Satoh Y., Akita H., Toyonaga Y., Ishihara T., Nakamura H., Iwai N., Nakamura H., Kuno K., Kmiya H., Kitamura K., Inoue M., Nishi H., Nishimura T., Sugita K., Takagi M., Aoki S., Kobayashi Y., Higashino H., Kobayashi Y., Haruta T., Kurashige T., Tomoda T., Motohiro T., Hirata T., Aramaki M., Ono E., Hashimoto N., Tominaga K., Tsuji Y., Hayashi K., Jpn. J. Antibiotics, 47, 57-83 (1994).
33. Kimura T., Sato M., Nonoyama M., Yago K., Ishii M., Sunakawa K., Jpn. J. Chemother., 54, 520-525 (2006).
34. Burton M. E., Shaw L. M., Schentag J. J., Evans W. E., "Applied Pharmacokinetics & Pharmacodynamics," Lippincott Williams & Wilkins., pp. 213-230 (2006).